european end-to-end CDMO company, pharma services

GMP

quality control of biologics

Quality Control of Biologics Ensuring Safety Through Aggregation Analysis

Analytics, Biologics, GMP, Proteins
ADC Manufacturing Services

ADC Manufacturing – A Comprehensive Guide to Drug Substance Manufacturing Services

Antibody-drug conjugates, GMP, Manufacturing
bioprocess scale up

Bioprocess Scale-Up from Lab Scale to Commercial GMP Manufacturing 

Clinical trials, GMP, Manufacturing
Navigating regulatory approval of biologics: A guide for emerging biotechs Bringing a biologic to market is an increasingly complex task, especially for small and mid-sized biotech companies with limited regulatory infrastructure. Meeting sometimes divergent EMA and FDA expectations, following increasingly complex regulations, and avoiding pitfalls related to documentation requires early planning and cooperation. Cross-functional alignment is also crucial to avoid issues related to comparability and process development/design space/process validation. This whitepaper outlines the key considerations in regulatory planning and biologics development, offering actionable insights for sponsors preparing their therapies for market. Bringing a biologic to market is a complex task, but with strategic planning and the right partners, emerging biotechs can overcome the regulatory hurdles with confidence. Mabion’s deep understanding of both EU and US regulatory requirements, coupled with extensive hands-on experience in biologics development and manufacturing, positions us as an ideal partner for companies seeking to streamline their path to approval.

Navigating Regulatory Approval of Biologics: A Guide for Emerging Biotechs

EMA, FDA, GMP, Regulatory
microbiological cleaning in cleanrooms

Microbiological Cleaning in Cleanrooms in CDMO Operation

GMP, Microbiology
Quality in cooperation with biopharmaceutical company CDMO

Quality as the Basis for CDMO Partnership Success

GMP, Mabion